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Abstract. In the past 5 years “Next-generation” Sequencing (NGS) technologies 
have transformed genomics by delivering fast, inexpensive and accurate genome 
information changing the way we think about scientific approaches in basic, 
applied and clinical research. The inexpensive production of large volumes of 
sequence data is the main advantage over the automated Sanger method, 
making this new technology useful for many applications. In this chapter, a brief 
technical review of NGS technologies is given, along with the keys to NGS 
success and a broad range of applications for NGS technologies. 
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1.  Introduction 
Nearly three decades ago Fred Sanger [1] and Wally Gilbert [2] received the Nobel prize for 
chemistry sequencing technology (see Automated electrophoresis Technique in “Genomics: More 
than genes” in this issue). This technology known as “Sanger Sequencing” or “First-generation 
sequencing” has dominated the industry for almost two decades and led to a number of 
accomplishments, including the completion of the human genome sequence.  In 2004, the 
International Human Genome Sequencing Consortium reported a genome sequence with high 
accuracy and nearly completed coverage of the human genome [3]. The approach consisted in 
“Sanger sequencing” more than 20.000 large bacterial artificial chromosome clones in which each 
one contained 100 kb fragments of the human genome. This project was performed during 10 years 
with multiple groups and companies participating. Although many technical improvements were 
achieved in this era, like automated capillary electrophoresis among others, new inventions were 
needed for sequencing large numbers of genomes. Recent efforts have been directed towards new 
methods known as “Next-generation” sequencing (NGS) technologies, which are capable to 
sequence a complete human genome in one week. In 2004, the 454 FLX Pyrosequencer from 
Roche was the first NGS sequencer to become commercially available [4]. The Solexa 1G Genetic 
Analyzer from Illumina was commercialized in 2006 [5]. The SOLiD System from Applied 
Biosystems was launched in 2007 [6]. Most recently, a “Third-generation” of sequencers has 
emerged. The HeliScope from Helicos BioSciences started shipping in early 2008 [7] and PacBIO 
RS from Pacific Biosciences in 2010 [8]. Although the first new technology appeared in 2004 more 
than 1000 next-generation sequencing-related manuscripts have appeared in the literature. NGS 
technology is not only changing our sequencing approaches and lowering the associated time and 
costs, it is also opening a wide variety of applications, types of biological samples, and new areas 
of biological inquiry. 
2.  Methodology 
2.1.  Principles of NGS technology 
The principle of the NGS technologies can be summarized as the sequencing of a multiple-parallel 
array of DNA features using interactive cycles of enzymatic manipulation and imaging-based data 
collection [9]. Although the different platforms are quite diverse in sequencing biochemistry and 
generating the array, their work flow is conceptually similar. The first step consists in Library 
construction which is achieved by random fragmentation of DNA, followed by an in vitro ligation 
of common adaptor sequences. The second step implies the generation of clonally clustered 
amplicons to serve as sequencing templates. Polymerase Chain Reaction (PCR) amplicons derived 
from a single library molecule end up spatially clustered, either to a single location on a planar 
substrate (bridge PCR [10, 11], or to the surface of micron-scale beads, which can be recovered and 
arrayed (emulsion PCR [12]). Subsequently, the sequencing process itself consists of alternating 
cycles of enzyme-driven biochemistry and imaging-based data acquisition (Figure 1). Most of the 
platforms use sequencing by synthesis, that is, serial extension of primed templates, but the enzyme 
driving the synthesis can be either a polymerase [13] or a ligase [14]. Data are acquired by imaging 
of the full array at each cycle. 
Besides their technical differences, other main concepts differ between platforms are: length of 
the generated sequences, production capacity that each platform can achieve per run, real-time 
DNA sequencing, and no need to amplify the sample before sequencing. These important points 
can lead to choosing one platform or other depending on the organism, application or expected 
result. Among the NGS platforms, the FLX-GS from Roche is the only one capable to generate 
long reads (average fragment length is around 400bp) but its sequencing capacity is low (350-
400Mb). On the contrary, other platforms get their strength in their sequencing capacity. HighSeq 
2000 from Illumina generates up 200Gb per run and 5050XL SOLiD system produces up to 20-30 
Gb per day with the inconvenience that their fragment length is among 50-100bp. This is an 
important issue in order to determine which platform is optimal for your experiment. For example, 
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if a biological sample is an unknown genome, longer reads are needed to assemble it, but if your 
sample has a reference genome available and the study consists in variation discovery in 
individuals, high sequencing capacity plays a key role. On the other hand, creating great 
expectations, and already in the final experimental stage, are the “Third-generation” sequencers. 
This is the case of the new Real-time sequencing machine from Pacific BioSciences, which 
harnesses the natural activity of key enzymes involved in the synthesis and regulation of DNA, 
RNA or proteins. Also, there is the HelicoScope, which ADN amplification is not needed before 
sequencing, this being really interesting to avoid amplification bias, although in the present its 
fragment average-length is too short. 
Figure 1: Work flow of Next Generation of DNA Sequencing. 
2.2 Keys to NGS success: NGS vs. Sanger  
Under standard conditions, Sanger sequencing results in a read length between 700-1000 bases. 
These are relatively long read lengths compared with NGS methods (400bp-Roche, 75bp-Solexa 
and 50bp-SOLiD). However, first generation sequencing is limited by the small amounts of data 
that can be processed per unit of time. The major advance offered by NGS is the ability to produce 
an enormous volume of data inexpensively [15]. In fact, the first version of the 454’s instrument 
could easily generate a throughput equivalent to that, or more than 50 Applied Biosystem’s 
3730XL at about one-sixth of the cost [16]. The array based sequencing approach, where hundreds 
of millions of reads are obtained in parallel on a small area, lows the cost of DNA sequence 
production since the same reagent volume is used for all the sequences at once (Figure 2). 
Another important point is the in vitro construction of a sequencing library, followed by in vitro 
clonal amplification to generate sequencing features, avoiding “E. coli” transformation and colony 
picking. Both steps are possible thanks to the common adaptors ligated in the library construction. 
These adaptors are also the responsible to extremely reduce the time, and consequently the cost of 
sequencing.  
The accuracy, the degree to which a reconstructed sequence is free from errors, is one of the 
topics that can be considered as a disadvantage of NGS vs. Sanger sequencing although the greater 
output overcomes this challenge. NGS platforms can produce high number of reads providing 
greater depth and sequence confidence.  Controversially, this great output from NGS technology 
comes with data management and analysis challenges. Significant computational infrastructure is 
required to process raw data generated by the sequencers and assemble or align them into contigs 
or scaffolds. But not only the computational infrastructure is a problem, a limited set of 
applications are covered with the instrument manufacturers software, and the need of specialized 
bioinformatitians is crucial for the success of this technology (see “Bioinformatics: making large-
scale science happen” in this issue). 
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Figure 2. Results obtained from a run performed in a GS-FLX instrument from Roche at the 
Genomic Unit, CCiTUB. The fluidics subsystem ensures accurate reagent dispensing and flows the 
sequencing reagents across the wells of the PicoTiterPlate device. Panel A shows raw density of the 
beads load in a PicoTiterPlate. Panel B represents the quality control of all the reads sequenced in 
the same run. Panel C is an augmented area of a PicoTiterPlate: green circles represent pass filter 
wells, red circles are beads that contain the key pass (common adaptor) but the quality control 
considers that this reads are not good, blue and orange are control beads and purple represents 
empty  beads,  no common adaptor has been ligated. Chart D shows all the reads from a GS-FLX 
run and their distribution by length (bp). 
3.  Examples of applications 
“Next-generation” DNA sequencing is accelerating biological and biomedical research, by 
enabling the comprehensive analysis of whole genomes, transcriptomes, and interactomes to 
become inexpensive, routine and wide spread [17]. Important applications include novel whole 
genomes and transcriptomes sequencing, full-genome resequencing or more targeted discovery of 
mutations or polymorphisms, mapping structural rearrangements, DNA-protein interactions 
through chromatin immunoprecipitation sequencing, gene expression, discovering noncoding 
RNAs, ancient genomes, metagenomics, and other applications that will appear over the next few 
years. 
3.1.  Novel whole genomes and transcriptomes sequencing 
When we talk about genomic revolution, this is one of the applications that better shows the 
concept. During the last decade only researchers interested in human, rat, mouse and a few more 
had the genomic tools to develop their research since a reference genome and kits were available. 
NGS brings the opportunity to sequence what you want because no sequence knowledge is needed 
and it is relatively inexpensive and fast. For example, characterizing transcripts through sequences 
rather than through hybridization to a chip is advantageous in many ways, most importantly, 
because the sequencing approach does not require the knowledge of the genome sequence as a 
prerequisite and new transcripts can be described. From our experience in the Genomic Unit of the 
CCiTUB, a good strategy for a de novo transcriptome project consists in normalize the cDNA to 
generate full-length-enriched double stranded (ds) cDNA with equalized concentrations of different 
transcripts [18]. The cDNA normalization enhances the potential of the GS-FLX sequencing 
technology, since the equalized cDNA library can be sequenced without having an enormous 
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amount of repeated transcripts and obtaining a wide range of interested transcripts represented 
(Figure 3). Once this information is assembled and annotated, new genomic tools can easily be 
created (custom arrays, another NGS runs, Real-time PCR (see RT-PCR technology “Genomics: 
More than genes” in this issue)) to study gene expression under different conditions. 
Figure 3: cDNA normalization results run in a Agilent 2100 Bioanalyzer at the Genomic Unit, 
CCiTUB. Panel A shows ds cDNA not normalized, panel B shows the same sample normalized 
and the panel C shows a gel where the most predominant transcripts have partially been enzymatic 
digested obtaining an equalized concentrations of all different transcripts. 
3.2.  Microsatellite discovery 
Microsatellite discovery of non-model organism is another example where NGS are helping to 
open new areas of biological inquiry. Microsatellites are short segments of DNA that have a 
repeated sequence such as CACACACA, and they tend to occur in non-coding DNA. Over time, as 
animals in a population breed, they will recombine their microsatellites during sexual reproduction 
and the population will maintain a variety of microsatellites that is characteristic for that population 
and distinct from other populations which do not interbreed. NGS technologies are drastically 
reducing the time previously used by scientists to discover new markers to use in their research. 
Experiments performed in our lab showed that running 1/6 of a PicoTiterPlate in the GS-FLX 
system was able to generate over one hundred potential perfect microsatellites (di-, tri-, and 
tetranucleotides) with at least ten repeats ready to use by automated capillary electrophoresis (see 
Automated capillary electrophoresis “Genomics: More than genes” in this issue).  
3.3.  Targeted discovery of mutations or polymorphisms 
For genomic resequencing, that is sequencing variation discovery in individuals of species for 
which a reference genome is available,  a specific region of the genome across more individuals is 
frequently used in contrast to study the whole genome in fewer individuals. Some companies 
(NimbleGen, Qiagen, Fluidigm, RainDance) are developing different tools to target capture regions 
of the DNA. These strategies permit sequence specific genome regions to which a disease 
phenotype has been mapped, or exons of specific candidate genes belonging to disease, or the full 
complement of protein-coding DNA sequences.   
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